Table 4.

Multivariate analysis of prognostic factors for progression-free survival

	Univariate analysis		Multivariate analysis
Variable	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Gender  Male vs Female	0.91 (0.47–1.76)	0.79
Age (years), median, range  <75 vs ≥75	0.71 (0.37–1.38)	0.31
Performance status  0–1 vs 2–3	1.66 (0.84–3.30)	0.15	Excluded
EGFR genotype  Exon 19 deletion vs  L858R point mutation	1.90 (1.06–3.74)	0.041	2.66 (1.28–5.54)	0.009
Smoking status  Current smoker vs  Never or former light smoker	1.18 (0.59–2.34)	0.64
Stage  Postoperative recurrence vs  Stage IV	1.80 (0.75–4.32)	0.19	2.46 (0.99–6.18)	0.052
Brain metastasis  Positive vs Negative	1.78 (0.94–3.36)	0.078	Excluded
Number of prior regimens  0 vs ≥1	2.80 (1.39–5.68)	0.026	2.77 (1.37–5.60)	0.004

Abbreviation: EGFR, epidermal growth factor receptor.